Paris, France (September 2, 2004) - Aureus Pharma, a leading knowledge management based company and a solution provider for the Life Sciences industry, announced today the release of new versions of its AurSCOPE databases for GPCR and ADME/Drug-Drug Interactions. In addition, Aureus Pharma also announced the initial release of a new AurSCOPE Ion Channel database product.

The AurSCOPE databases provide exhaustive chemical and biological information related to important drug targets (G-Protein Coupled Receptors and Ion Channels) and pharmaceutical topics such as ADME/Drug-Drug Interactions. These databases are integrated within a enterprise knowledge management system and can be searched via a web-based interface. Chemists and biologists can use this powerful enterprise system to identify, validate and prioritize in parallel new targets and ligands for drug discovery.

“Researchers are now able within Aureus Pharma’s knowledge management platform to optimally leverage the vast amount of data available within the scientific literature.” said Dr. André Michel, CEO of Aureus Pharma. “This data is a valuable source of knowledge and innovation to accelerate drug discovery”.

About AUREUS PHARMA

Aureus Pharma headquartered in Paris, France, is a privately held leading knowledge management based drug discovery company and a solution provider for the life sciences industry, founded in 2000. Aureus Pharma proposes a novel solution combining computerized knowledge management systems with experimental methods in order to accelerate new drug discovery. This mission fits with the need to innovate in therapeutic target identification and to discover safer and more specific drugs developing proprietary strategies based on “chemogenomics” concepts. Further information about Aureus Pharma is available on the World Wide Web at: www.aureus-pharma.com